Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Other Pulmonary Disorders01:17

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Chronic Obstructive Pulmonary Disease I: Introduction01:23

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunotherapy-related interstitial lung disease: a call to improve risk stratification and diagnostic consistency.

ERJ open research·2026
Same author

Boltzmann optical thermometry for cryogenics.

The Review of scientific instruments·2024
Same author

Drug-Induced Interstitial Lung Diseases.

Immunology and allergy clinics of North America·2023
Same author

Chest Involvement in Inflammatory Bowel Disease.

Pediatric allergy, immunology, and pulmonology·2022
Same author

The Spectrum of Airway Involvement in Inflammatory Bowel Disease.

Clinics in chest medicine·2022
Same author

Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement.

American journal of respiratory and critical care medicine·2019

Related Experiment Video

Updated: Jul 6, 2026

Pseudomonas aeruginosa Induced Lung Injury Model
07:24

Pseudomonas aeruginosa Induced Lung Injury Model

Published on: October 29, 2014

[Drug-induced lung diseases].

Philippe Camus1

  • 1Service de pneumologie et de réanimation respiratoire, hôpital du Bocage, 21000 Dijon. philippe.camus@chu-dijon.fr

La Revue Du Praticien
|March 7, 2008
PubMed
Summary

Drug-induced interstitial pneumonias are a key consideration in diagnosing lung conditions. Diagnosis requires evaluating clinical, imaging, and chronological factors alongside reported drug associations.

Area of Science:

  • Pulmonary Medicine
  • Pharmacology
  • Radiology

Context:

  • Drug-induced interstitial pneumonias (DIIPs) are increasingly recognized as a significant cause of interstitial lung disease (ILD).
  • Systematic consideration of DIIPs is crucial in the differential diagnosis of various interstitial lung diseases.
  • The clinical presentation of DIIPs can range from acute to chronic, with the same agent potentially causing different ILD patterns.

Purpose:

  • To highlight the importance of including drug-induced interstitial pneumonias in the differential diagnosis of interstitial lung diseases.
  • To emphasize the variable clinical and temporal presentations of drug-induced interstitial pneumonias.
  • To underscore the diagnostic challenges and criteria for identifying drug-induced interstitial pneumonias.

Summary:

More Related Videos

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation
11:07

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation

Published on: July 6, 2019

Related Experiment Videos

Last Updated: Jul 6, 2026

Pseudomonas aeruginosa Induced Lung Injury Model
07:24

Pseudomonas aeruginosa Induced Lung Injury Model

Published on: October 29, 2014

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation
11:07

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation

Published on: July 6, 2019

  • Drug-induced interstitial pneumonias present acutely, sub-acutely, or chronically, with some drugs capable of inducing varied ILD manifestations (e.g., amiodarone).
  • No single definitive diagnostic criterion exists for DIIPs.
  • Diagnosis relies on integrating clinical findings, imaging characteristics, the timeline of pulmonary symptoms, and the frequency of reported cases linked to the suspected drug.

Impact:

  • Improved diagnostic accuracy for interstitial lung diseases by systematically considering drug etiologies.
  • Enhanced clinical awareness of the diverse presentations and diagnostic complexities of drug-induced lung injury.
  • Facilitates timely identification and cessation of offending agents, potentially improving patient outcomes in interstitial pneumonias.